Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy

Oncotarget

Volumn 7, Issue 28, 2016, Pages 43616-43628

  Huang, Dan ^a   Zhang, Shuang ^a   Zhong, Ting ^a   Ren, Wei ^a   Yao, Xin ^a   Guo, Yang ^a   Duan, Xiao Chuan ^a   Yin, Yi Fan ^a   Zhang, Shu Shi ^a   Zhang, Xuan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anti tumor activity; Combretastatin A4; Glioma; NGR; Vascular mimicry

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARGINYLGLYCYLARGININE MODIFIED LIPOSOME CONTAINING COMBRETASTAIN A4; UNCLASSIFIED DRUG; COMBRETASTATIN A4 PHOSPHATE; LIPOSOME; OLIGOPEPTIDE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BRAIN; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG EFFECTS; DRUG SCREENING; ENDOTHELIUM CELL; FLUORESCENCE IMAGING; KAPLAN MEIER METHOD; MULTIPLE CHRONIC CONDITIONS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE CHRONIC CONDITIONS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; OPTICAL IMAGING; STILBENES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84978656508     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9889     Document Type: Article

References (34)

1. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010; 468:824-8.
2. Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014; 23:199-210.
3. De Bonis P, Marziali G, Vigo V, Peraio S, Pompucci A, Anile C, Mangiola A. Antiangiogenic therapy for highgrade gliomas: current concepts and limitations. Expert Rev Neurother. 2013; 13:1263-70.
4. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol. 2012; 124:763-75.
5. Jain RK, Carmeliet P. SnapShot: Tumor angiogenesis. Cell. 2012; 149:1408-1408.e1.
6. Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu D, Yu X, Tian Y. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med. 2015; 19:315-26.
7. Wang SY, Ke YQ, Lu GH, Song ZH, Yu L, Xiao S, Sun XL, Jiang XD, Yang ZL, Hu CC. Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol. 2013; 112:339-45.
8. Huang M, Ke Y, Sun X, Yu L, Yang Z, Zhang Y, Du M, Wang J, Liu X, Huang S. Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1a. Oncol Rep. 2014; 32:1973-80.
9. Chen YS, Chen ZP. Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer. 2014; 33:74-9.
10. Scully S, Francescone R, Faibish M, Bentley B, Taylor SL, Oh D, Schapiro R, Moral L, Yan W, Shao R. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. J Neurosci. 2012; 32:12950-60.
11. Ying M, Chen G, Lu W. Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems. Curr Pharm Des. 2015; 21:3066-75.
12. Liu Y, Mei L, Yu Q, Xu C, Qiu Y, Yang Y, Shi K, Zhang Q, Gao H, Zhang Z, He Q. Multifunctional Tandem Peptide Modified Paclitaxel-Loaded Liposomes for the Treatment of Vasculogenic Mimicry and Cancer Stem Cells in Malignant Glioma. ACS Appl Mater Interfaces. 2015; 7:16792-801.
13. Feng X, Yao J, Gao X, Jing Y, Kang T, Jiang D, Jiang T, Feng J, Zhu Q, Jiang X, Chen J. Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy. ACS Appl Mater Interfaces. 2015; 7:27885-99.
14. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998; 279:377-80.
15. Zhao BJ, Ke XY, Huang Y, Chen XM, Zhao X, Zhao BX, Lu WL, Lou JN, Zhang X, Zhang Q. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target. 2011; 19:382-90.
16. Luo LM, Huang Y, Zhao BX, Zhao X, Duan Y, Du R, Yu KF, Song P, Zhao Y, Zhang X, Zhang Q. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGRmodified liposomes containing paclitaxel. Biomaterials. 2013; 34:1102-14
17. Nagaiah G, Remick SC. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol. 2010; 6:1219-28.
18. Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, Colantuoni G. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist. 2009; 14:612-20.
19. Liu L, Mason RP, Gimi B. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts. Cancer Lett. 2015; 356:462-9.
20. Huang Y, Chen XM, Zhao BX, Ke XY, Zhao BJ, Zhao X, Wang Y, Zhang X, Zhang Q. Antiangiogenic Activity of Sterically Stabilized Liposomes Containing Paclitaxel (SSL-PTX): In Vitro and In Vivo. AAPS PharmSciTech. 2010; 11:752-9.
21. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014; 20:5612-9.
22. Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014; 35:7610-21.
23. Li XY, Zhao Y, Sun MG, Shi JF, Ju RJ, Zhang CX, Li XT, Zhao WY, Mu LM, Zeng F, Lou JN, Lu WL. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials. 2014; 35:5591-604.
24. Guo JQ, Zheng QH, Chen H, Chen L, Xu JB, Chen MY, Lu D, Wang ZH, Tong HF, Lin S. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int J Oncol. 2014; 45:1065-72.
25. Chen X, Zhang H, Zhu H, Yang X, Yang Y, Yang Y, Min H, Chen G, Liu J, Lu J, Cheng H, Sun X. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer. Tumour Biol. 2016; 37:4679-88.
26. Ling GQ, Liu YJ, Ke YQ, Chen L, Jiang XD, Jiang CL, Ye W. All-trans retinoic acid impairs the vasculogenic mimicry formation ability of U87 stem-like cells through promoting differentiation. Mol Med Rep. 2015; 12:165-72.
27. Liu W, Meng M, Zhang B, Du L, Pan Y, Yang P, Gu Z, Zhou Q, Cao Z. Dehydroeffusol effectively inhibits human gastric cancer cell-mediated vasculogenic mimicry with low toxicity. Toxicol Appl Pharmacol. 2015; 287:98-110.
28. Qiao L, Liang N, Zhang J, Xie J, Liu F, Xu D, Yu X, Tian Y. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med. 2015; 19:315-26.
29. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC, Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta. 2010; 1806:18-28.
30. Zhang Y, Sun X, Huang M, Ke Y, Wang J, Liu X. A novel bispecific immunotoxin delivered by human bone marrowderived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas. Drug Des Devel Ther. 2015; 9:2947-59.
31. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006; 1:1112-6.
32. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006; 5:2348-57.
33. Cui YF, Liu AH, An DZ, Sun RB, Shi Y, Shi YX, Shi M, Zhang Q, Wang LL, Feng Q, Pan GL, Wang Q. Claudin-4 is required for vasculogenic mimicry formation in human breast cancer cells. Oncotarget. 2015; 6:11087-97.
34. Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, Yao X, Wang C, Zhang WQ, Zhang X, Zhang Q. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release. 2016; 222:56-66. doi: 10.18632/oncotarget.3571.